West Pharmaceutical Services (WST) to Release Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) will post its quarterly earnings results before the market opens on Thursday, April 25th. Analysts expect West Pharmaceutical Services to post earnings of $1.31 per share for the quarter. West Pharmaceutical Services has set its FY24 guidance at $7.50-7.75 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, February 15th. The medical instruments supplier reported $1.83 EPS for the quarter, topping the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a net margin of 20.12% and a return on equity of 21.60%. The firm had revenue of $732.00 million for the quarter, compared to analysts’ expectations of $740.43 million. During the same period in the previous year, the firm posted $1.77 EPS. The company’s revenue for the quarter was up 3.3% on a year-over-year basis. On average, analysts expect West Pharmaceutical Services to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

West Pharmaceutical Services Trading Up 3.9 %

West Pharmaceutical Services stock opened at $389.98 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.88 and a quick ratio of 2.24. The firm has a 50-day moving average of $377.77 and a 200-day moving average of $364.11. The company has a market cap of $28.55 billion, a price-to-earnings ratio of 49.49, a P/E/G ratio of 6.36 and a beta of 1.04. West Pharmaceutical Services has a one year low of $310.42 and a one year high of $415.73.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Wednesday, April 24th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, April 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.21%. West Pharmaceutical Services’s dividend payout ratio is 10.15%.

Insider Buying and Selling

In other West Pharmaceutical Services news, SVP Silji Abraham sold 7,012 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $365.00, for a total value of $2,559,380.00. Following the transaction, the senior vice president now directly owns 4,660 shares of the company’s stock, valued at approximately $1,700,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Silji Abraham sold 7,012 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $365.00, for a total value of $2,559,380.00. Following the completion of the sale, the senior vice president now owns 4,660 shares of the company’s stock, valued at $1,700,900. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric Mark Green sold 64,132 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $359.85, for a total transaction of $23,077,900.20. Following the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at $55,023,943.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,978 shares of company stock valued at $26,653,772. Company insiders own 0.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. KeyCorp upped their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 13th. UBS Group cut their price target on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research note on Friday, February 16th. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, Jefferies Financial Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their target price for the company from $323.00 to $536.00 in a report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $435.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.